tbuckley/cabot-search huggingface dataset:
Association News
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Die Gestagene
Authors: Victor A. Drill
Journal: JAMA (1969)

Dr. Junkmann and his coauthors have prepared an organized, detailed, and documented summary of the important world literature on the gestagens (progestins). Progesterone is reviewed in detail, followed by data on the most important of the synthetic steroids with progestational activity that are presently used in medical practice. The book, written in German, is encyclopedic in nature. Various chapters deal with the chemical and physical properties and the absorption, distribution, excretion, and metabolism of progesterone and the synthetic gestagens; the effect of these steroids on metabolic processes; and their action on organ systems. The section on therapeutic uses reviews data on the use of the gestagens alone and in conjunction with estrogens. Selected readings of the text indicate that every important publication has been included. Although an index is not provided, the detailed table of contents should allow the reader to locate the information desired. It is extremely difficult for
Role of Fat Replacers in Diabetes Medical Nutrition Therapy
Journal: Diabetes Care (1998)

Foods with fat replacers have the potential to help people with diabetes reduce total and saturated fat intake and may therefore, in time, reduce the increased prevalence of dyslipidemia in type 2 diabetes. However, for these foods to have any potential benefit to people with diabetes, people with diabetes must learn to use them appropriately. People with diabetes should receive self-management training on how to identify ingredients that are fat replacers on labels, how to use the food label to determine serving sizes, and how to incorporate these foods into their food/meal plan, along with the selection of a wide variety of nutritious foods. Health professionals and people with diabetes need to keep current with the ever-changing market-place, available food products, and growing body of scientific literature. Additional research is needed to assess the impact of the use of fat replacers on the macronutrient content of the diet, metabolic parameters related to diabetes, and potential health and nutrition benefits for the person with diabetes.
Analysis of the prevalence of metabolic syndrome components and other factors as predictors of disease progression among an urban population with NAFLD and/or NASH
Authors: Anish Jammu, Hamed Dallali, Justin Lee, Sirajuddaula Kausar, Muhammad Khurram, Silva Cortez, Marzena Magnes, Magdy Elkhashab
Journal: Journal of Hepatology (2020)
Effects of Angiotensin Infusion on Catecholamine Uptake and Reactivity in Blood Vessels
Authors: PHILIP A. KHAIRALLAH, D. DAVILA, N. PAPANICOLAOU, N. M. GLENDE, PHILIPPE MEYER
Journal: Circulation Research (1971)

The interrelations between angiotensin and catecholamine uptake have been studied in rats. Angiotensin was infused for either 5, 30, or 120 minutes at three dose levels: 1, 12, and 45 ng/kg/min. With short exposures to angiotensin, effects were seen in kidney, uterus, and adrenal gland. These organs had been previously shown to bind the greatest amount of tritiated peptide administered intravenously. In the 5- and 30-minute experiments angiotensin inhibited uptake of either metaraminol or norepinephrine in most tissues, especially at the higher dose levels, with the exception of the adrenal gland where uptake was increased. After the two-hour infusion inhibition of uptake was seen in most organs. When high titer angiotensin II antibodies were administered intravenously, responses to iv angiotensin were abolished. At this stage the uptake of tritiated norepinephrine was increased in kidney, heart, spleen, and vas deferens, while it was decreased in the adrenal gland. To see whether these biochemical findings are related to a physiological role, contractile responses of isolated perfused arteries of rabbits were studied. Angiotensin potentiated the increase in perfusion pressure after the infusion of norepinephrine, while angiotensin II antibodies decreased this response. Thus, it is concluded that angiotensin can modify the uptake and, hence, the inactivation of the sympathetic neurotransmitter and possibly by this mechanism alter the physiological response to norepinephrine and sympathetic stimulation.
In Reply:
Authors: Paul Moreton
Journal: Journal of Clinical Oncology (2005)

estimates of the survival distributions are biased, the statistical tests are invalid, and the conclusions are misleading.Responders should only be counted as at risk for death or other event (as a responder) following the time that the response is observed.One valid approach to assessing the impact of response on outcome would be to compare patients by response at some fixed landmark following the onset of therapy.For instance, the authors could classify patients by response at 6 months following the onset of therapy.Some patients will have progressed; some will be in partial response; some will be in complete response (CR), but still minimal residual disease positive (MRDϩ) and some will be in a MRD negative (MRD-) CR.Note that a patient who attains an MRD ϩ CR at month 4 and an MRD-CR at month 12 would be classified in this analysis as MRDϩ CR at the 6 month landmark.The analysis of MRD status further complicates this situation.MRD by flow is presented only for patients achieving a CR; this is appropriate, as patients with disease detectable by other methods should not be included in an MRD analysis.Therefore, a comparison of outcome between MRDϩ and MRD-patients among those achieving CR could be valid, if the landmark analysis cited above were performed.The authors continued alemtuzumab treatment until maximal response, so that an interval response at a landmark time would need to be assessed.It may well be that an MRD-remission leads to an improved overall and treatment-free survival, but the authors' analysis is in error and cannot be used as evidence of this.
Auscultation
Authors: M. Saleem Seyal
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DISAPPOINTMENTS OF ENDOCRINOLOGY
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ugeskrift for Laeger, Copenhagen
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BET Bromodomain Blockade Enhances Ikaros Inhibition By Lenalidomide Therapy Providing Additional Activity in In Vitro and In Vivo Models of Multiple Myeloma
Authors: Carlos Fernández de Larrea, Tania Díaz, Vanina Rodriguez, Ester Lozano, Patricia Pérez-Galán, Mari-Pau Mena, Marcos Calderón, Laura Rosiñol, Antonio Martínez, Natalia Tovar, Gael Roue, Joan Bladé
Journal: Blood (2016)
NEW YORK LETTER.
Authors: None P. B. P.
Journal: JAMA (1885)

New York, Dec. 20, 1884. For some time past the subject of cholera has received a good deal of attention in the societies here, and it may, perhaps, be of interest to note the views of some of the prominent medical men of New York in regard to Koch's theory of the disease so far as they have been expressed at these meetings. The one who has expressed most fully and forcibly his belief in the probable correctness of the opinions of Koch is Dr. Austin Flint, Sr. That Dr. Flint would be likely to take this position whenever he enunciated his convictions on the subject was rendered almost certain by the elaborate paper which he read in support of the essential dependence of tuberculous disease on the<i>bacillus tuberculosis</i>at the first public meeting of the New York County Medical Association in January last. At the October meeting of
Viruses as precipitants of asthmatic attacks in children
Authors: T. E. Minor
Journal: JAMA (1974)

Evidence for the exacerbation of asthma by specific infectious agents was sought in an October 1971 through May 1972 outpatient study of 16 children with histories of wheezing associated with apparent symptomatic respiratory infections (SRI). Clinical data were collected daily, and pharyngeal and nasal specimens were obtained routinely for microbiological analyses. Subjects experienced 61 episodes of asthma, and 42 of these were coincident with an apparent SRI. Asthmatic attacks occurred with 38 of 49 severe SRI, but only 4 of 22 mild SRI were similarly associated. Asthma was precipitated during 21 of 23 severe SRI of viral origin, but in only one of six severe SRI of bacterial origin. Fourteen of 15 rhinovirus infections that resulted in severe SRI and all episodes of A<sub>2</sub>/Hong Kong influenza were associated with attacks of asthma. No asthma was noted during episodes of asymptomatic virus shedding.
MEDICAL INSPECTION OF PUPILS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Laboratory-Acquired Meningococcal Disease—United States, 2000
Journal: JAMA (2002)

Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis among older children and young adults in the United States. N. meningitidis usually is transmitted through close contact with aerosols or secretions from the human nasopharynx. Although N. meningitidis is regularly isolated in clinical laboratories, it has infrequently been reported as a cause of laboratory-acquired infection. This report describes two probable cases of fatal laboratory-acquired meningococcal disease and the results of an inquiry to identify previously unreported cases. The findings indicate that N. meningitidis isolates pose a risk for microbiologists and should be handled in a manner that minimizes risk for exposure to aerosols or droplets.
Incorrect Information in: CDC Advisors Suggest Streamlining Postexposure Prophylaxis for Rabies
Authors: Richard Piekarz, Ari Zivotofsky
Journal: JAMA (2010)

onstrated in rabbinic decisions.For example, bullfighting has been prohibited, with an admonishment that even attending such events erodes a compassionate nature and implants a sense of accepting cruelty (Yechaveh Da'at 3:66).However, this principle is not unlimited; for example, a 1978 ruling determined that medical animal experimentation is permitted even if it causes pain to the animal because of the overriding human need (Tzitz Eliezar 14:68).
Cerebral Blood Flow Constant Despite Variations in Arterial Pressure
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Predictors of liver transplantation outcomes
Authors: Natalie Berntsen, Olav Klin- Genberg, Kirsten Boberg, Tom Karlsen, Johannes Hov, Christopher Sonnenday, Michael Volk, Michael Englesbe
Journal: Hepatology (2013)

IgG4>1.35 and IgG4>2.01respectively.The HLA-B*08 allele, consistently observed as the top genetic risk factor in PSC, was less prevalent in patients with high than low IgG4 (29% vs 42%, P=0.02, for cut-off IgG4>1.35 and 26% vs 41%, P=0.05, for cut-off IgG4>2.01).In contrast, the PSC-associated alleles HLA-B*07 and DRB1*15 were more prevalent in PSC with high than low IgG4, but only when applying the IgG4>2.01cut-off (HLA-B*07: 24% vs 13%, P=0.04 and DRB1*15: 26% vs 14%, P=0.04, for high vs low IgG4, respectively).When comparing patients with healthy controls, HLA-DRB1*15 was significantly associated only with PSC with IgG4>2.01 (26% vs 15%, P=0.05), while there was no association with HLA-DRB1*15 in this PSC population as a whole (P=0.90).Clinically, IgG4>1.35 was associated with shorter liver transplantation free survival (P=0.05) and shorter survival to the end-point of death only (P=0.007), while there were no differences between high and low IgG4 regarding gender (87% vs 75% male, P=0.09) or inflammatory bowel disease (IBD) (82% vs 82%).However, in patients with high IgG4 (>1.35),HLA-B*08 was more prevalent in patients with than without IBD (35% vs 6%, P=0.03), while IBD did not define genetically different subgroups in patients with low IgG4.Conclusions: We report for the first time on genetic associations for elevated IgG4 levels in PSC.Our findings suggest that the phenotypic heterogeneity represented by the IgG4 response contribute to the complex HLA associations observed in PSC.The possibility that elevated IgG4 concentration designate a genetic as well as clinical subgroup should be taken into account in further studies, ultimately aiming to identify patients suitable for immunosuppressive therapy or other treatment options.
Cancer Pain
Authors: John M. Merrill
Journal: JAMA (1993)

Pain has remained a common affliction and a constant adversary for patients and their physicians. What appears to be new is the attention to pain in conferences and publications, with government guidelines published (by the US Public Health Service) and prospective studies that attest to inadequate pain control. This text, a truly international work with 38 contributors from seven countries, addresses both the old, for example the opiate analgesics, and the new, such as high-tech delivery systems, thoroughly and objectively. Chapters detail intricate neurolytic blocks and intraspinal drug delivery, but the new and novel are contrasted with the old and problematic in chapters such as "Complications of Invasive Procedures" and "Inadequate Outcome of Opioid Therapy." The 30 chapters and eight appendixes comprise the equivalent of four or five handbooks, depending upon one's specialty, for a variety of clinical specialists could obtain vital information here. Although a preference for a multidisciplinary
Natriuretic Peptides
Authors: Franklin H. Epstein, Ellis R. Levin, David G. Gardner, Willis K. Samson
Journal: New England Journal of Medicine (1998)

In 1981, de Bold and his colleagues made the seminal observation that infusion of extracts of atrial tissue into rats caused a copious natriuresis.1 This then led to the isolation and cloning of atrial natriuretic peptide, the first member of a family of peptides with potent natriuretic, diuretic, and vasorelaxant activity.2 Subsequent contributions from many investigators have expanded our understanding of the family of natriuretic peptides, their receptors, and their cellular actions that regulate physiologic functions. Studies using drugs to inhibit the function of some natriuretic peptide receptors or to prevent the degradation of natriuretic peptides have confirmed the importance . . .
Reactive Oxygen Species Signaling through Regulation of Protein Tyrosine Phosphorylation in Endothelial Cells
Authors: Viswanathan Natarajan, William M. Scribner, Mohammed Al-Hassani, Suryanarayana Vepa
Journal: Environmental Health Perspectives (1998)

Tyrosine phosphorylation of proteins, controlled by tyrosine kinases and protein tyrosine phosphatases, plays a key role in cellular growth and differentiating.A wide variety of hormones, growth factors, and cytokines modulate cellular tyrosine phosphorylation to transmit signals across the plasma membrane to the nucleus.Recent studies suggest that reactive oxygen species (ROS) also induce cellular protein tyrosine phosphorylation through receptor or nonreceptor tyrosine kinases.To determine whether protein tyrosine phosphorylation by ROS regulates endothelial cell (EC) metabolism and function, we exposed vascular ECs to H202 or H202 plus vanadate.This resulted in a time-and dose-dependent increase in protein tyrosine phosphorylation of several proteins (Mr 21-200 kDa), as determined by immunoprecipitation and Western blot analysis with antiphosphotyrosine antibody.Immunoprecipitation with specific antibodies identified increased tyrosine phosphorylation of mitogen-activated protein kinases (42-44 kDa), paxillin (68 kDa), and FAK (125 kDa) by ROS.An immediate signaling response to increased protein tyrosine phosphorylation by ROS was activation of phospholipases such as A2, C, and D. Suramin pretreatment inhibited ROS stimulation of phospholipase D (PLD), suggesting a role for growth factor receptors in this activation.Further, PLD activation by ROS was attenuated by N- acetylcysteine, indicating that intracellular thiol status is critical to ROS-mediated signal transduction.These results provide evidence that ROS modulate EC signal transduction via a protein tyrosine phosphorylation-dependent mechanism.